$RGEN News

Wall Street Analysts Believe Repligen (RGEN) Could Rally 25.72%: Here's is How to Trade

Repligen (NASDAQ:RGEN) Combines Strong Growth with a Promising Technical Breakout Setup

Wells Fargo Maintains Overweight on Repligen, Raises Price Target to $185

Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up

JP Morgan Maintains Overweight on Repligen, Raises Price Target to $175

Why Repligen (RGEN) Stock Is Up Today

Repligen (RGEN) Held An M&A Call With BioLife Solutions.

Repligen Corp (RGEN) Q2 2026 Earnings Call Highlights: Strong Growth and Raised Guidance Amidst ...

Repligen Q2 Earnings Call Highlights

Repligen Reports Q2 Revenue Growth and Raises Full-Year 2026 Guidance

Repligen Corporation (RGEN) Q2 2026 Earnings Call Transcript

Repligen (NASDAQ:RGEN) Rallies as Quality Stock Delivers Earnings Beat

Repligen (RGEN) Beats Q2 Earnings and Revenue Estimates

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q2 CY2026

Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Repligen Q2 Adj. EPS $0.54 Beats $0.45 Estimate, Sales $204.128M Beat $201.483M Estimate

Repligen Raises FY2026 Adj EPS Guidance from $1.97-$2.05 to $2.03-$2.09 vs $2.00 Est; Raises FY2026 Sales Guidance from $803.000M-$833.000M to $813.000M-$835.000M vs $822.537M Est

Repligen (RGEN) Q2 Earnings: What To Expect

Repligen to Expand Cell Therapy Capabilities With BioLife Buyout

Repligen Corporation (RGEN) M&A Call Transcript